Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels

enthalten in: Immunologic research | 2022

von Dobi, A. | Dubernet, A. | Rakoto, M. | +5

Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment—a population-based cohort study

enthalten in: Immunologic research | 2021

von Kridin, K. | Schonmann, Y. | Solomon, A. | +4